Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition

Journal of Virology

Volumn 82, Issue 8, 2008, Pages 4052-4063

  Tagmyer, Tara L ^a   Craigo, Jodi K ^a   Cook, Sheila J ^b   Even, Deborah L ^b   Issel, Charles J ^b   Montelaro, Ronald C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 90; LIVE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VACCINE; EPITOPE; PEPTIDE; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EQUINE INFECTIOUS ANEMIA VIRUS; FEMALE; HORSE; HUMORAL IMMUNITY; LENTIVIRINAE; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; BLOOD; CELL PROLIFERATION; CYTOTOXICITY TEST; GENETICS; HORSE DISEASE; IMMUNOLOGY; MONONUCLEAR CELL; SERODIAGNOSIS;

EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS;

ANIMALS; ANTIBODIES, VIRAL; CELL PROLIFERATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES; EQUINE INFECTIOUS ANEMIA; HORSES; INFECTIOUS ANEMIA VIRUS, EQUINE; LEUKOCYTES, MONONUCLEAR; NEUTRALIZATION TESTS; PEPTIDES; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 41949107948     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02028-07     Document Type: Article

References (68)

1. Albright-Fraiser, D. G., R. Reid, V. Graber, and E. Bailey. 1996. Polymorphism of DRA among equids. Immunogenetics 43:315-317.
2. Almond, N., R. Rose, R. Sangster, P. Silvera, R. Stebbings, B. D. Walker, and E. J. Stott. 1997. Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. J. Gen. Virol. 78:1919-1922.
3. Bailey, E. 1980. Identification and genetics of horse lymphocyte alloantigens. Immunogenetics 11:499-506.
4. Bailey, E. 1983. Population studies on the ELA system in American standardbred and thoroughbrcd mares. Anim. Blood Groups Biochem. Genet. 14:201-211.
5. Ball, J. M., K. E. Rushlow, C. J. Issel, and R. C. Montelaro. 1992. Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies. J. Virol. 66:732-742.
6. Barouch, D. H., T. M. Fu, D. C. Montefiori, M. G. Lewis, J. W. Shiver, and N. L. Letvin. 2001. Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. Immunol. Lett. 79:57-61.
7. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T.-M. Fu, W. Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, K. Beaudry, M. A. Lifton, C. E. Nickerson, W. L. Trigona, K. Punt, D. C. Freed, L. Guan, S. Dubey, D. Casimiro, A. Simon, M.-E. Davies, M. Chastain, T. B. Strom, R. S. Gelman, D. C. Montefiori, M. G. Lewis, E. A. Emini, J. W. Shiver, and N. L. Letvin. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486-492.
8. Bogers, W. J. M., C. Cheng-Mayer, and R. C. Montelaro. 2000. Developments in preclinical AIDS vaccine efficacy models. AIDS 4:5141-5152.
9. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
10. Chung, C., R. H. Mealey, and T. C. McGuire. 2005. Evaluation of high functional avidity CTL to Gag epitope clusters in EIAV carrier horses. Virology 342:228-239.
11. Clements, J. E., R. C. Montelaro, M. C. Zink, A. M. Amedee, S. Miller, A. M. Trichel, B. Jagerski, D. Hauer, L. N. Martin, and R. P. Bohm. 1995. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J. Virol. 69:2737-2744.
12. Cole, K. S., M. Murphey-Corb, O. Narayan, S. V. Joag, G. M. Shaw, and R. C. Montelaro. 1998. Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections. J. Virol. 72:7852-7859.
13. Cole, K. S., J. L. Rowles, B. A. Jagerski, M. Murphey-Corb, T. Unangst, J. E. Clements, J. Robinson, M. S. Wyand, R. C. Desrosiers, and R. C. Montelaro. 1997. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J. Virol. 71:5069-5079.
14. Connor, R. I., D. C. Montefiori, J. M. Binley, et al. 1998. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Virol. 72:7501-7509.
15. Couillin, I., B. Culmann-Penciolelli, E. Gomard, J. Choppin, J. P. Levy, J. G. Guillet, and S. Saragosti. 1994. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein. J. Exp. Med. 180:1129-1134.
16. Craigo, J. K., S. Durkin, T. J. Sturgeon, T. Tagmyer, S. J. Cook, C. J. Issel, and R. C. Montelaro. 2007. Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines. Vaccine 25:834-845.
17. Craigo, J. K., T. J. Sturgeon, S. J. Cook, C. J. Issel, C. Leroux, and R. C. Montelaro. 2006. Apparent elimination of EIAV ancestral species in a long-term inapparent carrier. Virology 344:340-353.
18. Craigo, J. K., B. S. Zhang, S. Barnes, T. L. Tagmyer, S. J. Cook, C. J. Issel, and R. C. Montelaro. 2007. Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc. Natl. Acad. Sci. USA 104:15105-15110.
19. Fraser, D. G., and E. Bailey. 1996. Demonstration of three DRB loci in a domestic horse family. Immunogenetics 44:441.
20. Fraser, D. G., and E. Bailey. 1998. Polymorphism and multiple loci for the horse DQA gene. Immunogenetics 47:487-490.
21. Fraser, D. G., S. R. Leib, B. S. Zhang, R. H. Mealey, W. C. Brown, and T. C. McGuire. 2005. Lymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challenge. Clin. Diagn. Lab. Immunol. 12:983-993.
22. Fraser, D. G., J. L. Oaks, W. C. Brown, and T. C. McGuire. 2002. Identification of broadly recognized, T helper 1 lymphocyte epitopes in an equine lentivirus. Immunology 105:295-305.
23. Gundlach, B. R., S. Reiprich, S. Sopper, R. E. Means, U. Dittmer, K. Matz-Rensing, C. Stahl-Hennig, and K. Uberla. 1998. Env-independent protection induced by live attenuated simian immunodeficiency virus vaccines. J. Virol. 72:7846-7851.
24. Hammond, S. A., S. J. Cook, D. L. Lichtenstein, C. J. Issel, and R. C. Montelaro. 1997. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 71:3840-3852.
25. Hammond, S. A., M. L. Raabe, C. J. Issel, and R. C. Montelaro. 1999. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Virology 262:416-430.
26. Harari, A., S. Petitpierre, F. Vallelian, and G. Pantaleo. 2003. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1 infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103:966-972.
27. Harrer, T., E. Harrer, S. A. Kalams, T. Elbeik, S. I. Staprans, M. B. Feinberg, Y. Cao, D. D. Ho, T. Yilma, and A. M. Caliendo. 1996. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res. Hum. Retrovir. 12:585.
28. Heeney, J. L., and S. A. Plotkin. 2006. Immunological correlates of protection from HIV infection and disease. Nat. Immunol. 7:1281-1284.
29. Howe, L., J. K. Craigo, C. J. Issel, and R. C. Montelaro. 2005. Specificity of serum neutralizing antibodies induced by transient immune suppression of inapparent carrier ponies infected with a neutralization- resistant equine infectious anemia virus envelope strain. J. Gen. Virol. 86:139-149.
30. Howe, L., C. Leroux, C. J. Issel, and R. C. Montelaro. 2002. Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype. J. Virol. 76:10588-10597.
31. Issel, C. J., and L. Coggins. 1979. Equine infectious anemia virus: current knowledge. J. Am. Vet. Med. Assoc. 174:727-733.
32. Jin, X., D. E. Bauer, S. E. Tuttleton, S. Lewin, A. Gettie, J. Blanchard, C. E. Irwin, J. T. Safrit, J. Mittler, L. Weinberger, L. G. Kostrikis, L. Zhang, A. S. Perelson, and D. D. Ho. 1999. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991-998.
33. Johnson, P. R., B. C. Schnepp, M. J. Connell, D. Rohne, S. Robinson, G. R. Krivulka, C. I. Lord, R. Zinn, D. C. Montefiori, N. L. Letvin, and K. R. Clark. 2005. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J. Virol. 79:955-965.
34. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune response with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
35. Kraft, Z., N. R. Derby, R. A. McCaffrey, R. Niec, W. M. Blay, N. L. Haigwood, E. Moysi, C. J. Saunders, T. Wrin, C. J. Petropoulos, M. J. McElrath, and L. Stamatatos. 2007. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J. Virol. 81:6402-6411.
36. Leroux, C., J. K. Craigo, C. J. Issel, and R. C. Montelaro. 2001. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies. J. Virol. 75:4570-4583.
37. Leroux, C., C. J. Issel, and R. C. Montelaro. 1997. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J. Virol. 71:9627-9639.
38. Li, F., J. K. Craigo, L. Howe, J. D. Steckbeck, S. Cook, C. Issel, and R. C. Montelaro. 2003. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J. Virol. 77:7244-7253.
39. Malhotra, U., F. Li, J. Nolin, M. Allison, H. Zhao, J. I. Mullins, S. Self, and M. J. McElrath. 2007. Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. J. Virol. 81:5225-5237.
40. Mascola, J., M. G. Lewis, G. Stiegler, D. Harris, T. VanCott, D. Hayes, M. Louder, C. Brown, C. Sapan, S. Frankel, Y. Lu, M. Robb, H. Katinger, and D. Birx. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
41. Mascola, J., G. Stiegler, T. VanCott, H. Katinger, C. Carpenter, C. Hanson, H. Beary, D. Hayes, S. Frankel, D. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
42. Matano, T., R. Shibata, C. Siemon, M. Connors, H. C. Lane, and M. A. Martin. 1998. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72:164-169.
43. McGuire, T. C., T. B. Crawford, and J. B. Henson. 1971. Immunofluorescent localization of equine infectious anemia virus in tissue. Am. J. Pathol. 62:283-294.
44. + cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins. J. Virol. 68:1459-1467.
45. Mealey, R. H., A. Sharif, S. A. Ellis, M. H. Littke, S. R. Leib, and T. C. McGuire. 2005. Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes. Virology 339:110-126.
46. Mealey, R. H., B. Zhang, S. R. Leib, M. H. Littke, and T. C. McGuire. 2003. Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus. Virology 313:537-552.
47. Metzner, K. J., W. J. Moretto, S. M. Donahoe, X. Jin, A. Gettie, D. C. Montefiori, P. A. Marx, J. M. Binley, D. F. Nixon, and R. I. Connor. 2005. Evaluation of CD8+ T-cell and antibody responses following transient increased viremia in rhesus macaques infected with live, attenuated simian immunodeficiency virus. J. Gen. Virol. 86:3375-3384.
48. Montelaro, R. C., J. M. Ball, and K. E. Rushlow. 1993. Equine retroviruses, p. 257-360. In J. A. Levy (ed.), The Retroviridae. Plenum Press, New York, NY.
49. Montelaro, R. C., and D. P. Bolognesi. 1995. Vaccines against retroviruses, p. 605-656. In J. A. Levy (ed.), The Retroviridae, vol. 4. Plenum Press, New York, NY.
50. Montelaro, R. C., K. S. Cole, and S. A. Hammond. 1998. Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. AIDS Res. Hum. Retrovir. 14:S225-S229.
51. Nilsson, C., B. Makitalo, R. Thorstensson, S. Norley, D. Binninger-Schinzel, M. Crange, E. Rud, G. Biberfeld, and P. Putkonen. 1998. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 12:2261-2270.
52. Norley, S., B. Beer, D. Binninger-Schinzel, C. Cosma, and R. Kurth. 1996. Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology 219:195-205.
53. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, A. Hurley, M. Markowitz, D. D. Ho, D. F. Nixon, and A. J. McMichael. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103-2106.
54. Pantaleo, G., and R. A. Koup. 2004. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10:806-810.
55. Payne, S. L., F. D. Fang, C. P. Liu, B. R. Dhruva, P. Rwambo, C. J. Issel, and R. C. Montelaro. 1987. Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV. Virology 161:321-331.
56. Perryman, L. E., K. O'Rourke, and T. C. McGuire. 1988. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J. Virol. 62:3073-3076.
57. Phillips, R. E., S. Rowland-Jones, D. F. Nixon, F. M. Gotch, J. P. Edwards, A. O. Ogunlesi, J. G. Elvin, J. A. Rothbard, C. R. M. Bangham, C. R. Rizza, and A. J. McMichael. 1991. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453-459.
58. Pitcher, C. J., C. Quittner, D. M. Peterson, M. Connors, R. A. Koup, V. C. Maino, and L. J. Picker. 1999. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5:518-525.
59. Polacino, P., V. Stallard, D. C. Montefiori, C. R. Brown, B. A. Richardson, W. R. Morton, R. E. Benveniste, and S.-L. Hu. 1999. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. J. Virol. 73:3134-3146.
60. Ridgely, S. L., B. Zhang, and T. C. McGuire. 2003. Response of ELA-A1 horses immunized with lipopeptide containing an equine infectious anemia virus ELA-A1-restricted CTL epitope to virus challenge. Vaccine 21:491-506.
61. Rinaldo, C., X. L. Huang, Z. F. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, and M. Cottrill. 1995. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:5838-5842.
62. Rwambo, P. M., C. J. Issel, K. A. Hussain, and R. C. Montelaro. 1990. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV). Arch. Virol. 111:275-280.
63. Schmitz, J., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, J. Ghrayeb, M. A. Forman, D. C. Montefiori, E. P. Rieber, N. L. Letvin, and K. A. Reimann. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-860.
64. Sharpe, S. A., A. Cope, S. Dowall, N. Berry, C. Ham, J. L. Heeney, D. Hopkins, L. Easterbrook, M. Dennis, N. Almond, and M. Cranage. 2004. Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to wild-type challenge, despite declining cytotoxic T lymphocyte responses to an immunodominant epitope. J. Gen. Virol. 85:2591-2602.
65. Tagmyer, T. L., J. K. Craigo, S. J. Cook, C. J. Issel, and R. C. Montelaro. 2007. Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus. J. Gen. Virol. 88:1324-1336.
66. Yang, O. O., P. T. N. Sarkis, A. Trocha, S. A. Kalams, R. P. Johnson, and B. D. Walker. 2003. Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. J. Immunol. 171:3718-3724.
67. Zhang, P. F., F. Cham, M. Dong, A. Choudhary, P. Bouma, Z. Zhang, Y. Shao, Y.-R. Feng, L. Wang, N. Mathy, G. Voss, C. C. Broder, and G. V. Quinnan, Jr. 2007. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc. Natl. Acad. Sci. USA 104:10193- 10198.
68. Zhang, W., S. M. Lonning, and T. C. McGuire. 1998. Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection. J. Virol. 72:9612-9620.